explore -WSS

explore

author：comprehensive 2025-09-30 00:36:58 - browse：42632

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

Fresh off of the news that its drug Wegovy may not just help people lose weight, but could also lower cardiac risks, Novo Nordisk doubled down on its obesity drug pipeline Thursday, acquiring a small Canadian biotech with a new approach to weight loss.

Novo will spend up to $1 billion to buy Inversago Pharma, which is developing an oral obesity drug that targets the cannabinoid receptor CB1. It’s the second big obesity acquisition this year, following Eli Lilly’s move to purchase startup Versanis Bio.

Drugs like Wegovy are in a class called GLP-1 drugs, which mimic the effects of the glucagon-like peptide 1 hormone that help people feel full by targeting the hormone’s receptors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Why depression after traumatic brain injury is distinct

WSS

Medicare coverage of Wegovy, once blocked, now looks possible

Protect nursing home residents from future pandemics

Decentralized clinical trials need collaboration to achieve wider use

Clinicians often fail to acknowledge the pain caused by long Covid

UCLA team creates talking throat patch for voice disorders

Ozempic cut risk of death in diabetes patients with chronic kidney disease

knowledge

explore

leisure time

Duchenne breakthrough therapy leaves behind pioneering families

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Drug repurposing or repositioning? The language matters

EPA limits use of carcinogenic gas for sterilizing medical devices

DIEP, the 'gold standard' of breast reconstruction, is under threat

Readout Newsletter: CAR

Walensky prepares to leave CDC — and Congress — behind

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Anesthesiologist group: stop taking Ozempic before surgery

Unmasking the 'centricity' illusion in clinical trials

focus

Lawsuit challenges CMS nursing home minimum staffing rule

U.S. death rates show how politics are affecting public health

Unmasking the 'centricity' illusion in clinical trials

Louisiana bill approved classifying abortion pills as controlled substances

Protect nursing home residents from future pandemics

Medicare coverage of Wegovy, once blocked, now looks possible

explore

focus

hotspot

knowledge